Clinically actionable biomarkers linked to adverse immune response- resulting from metal exposure - are limited. To address this much needed clinical priority, we are proposing to implement a comprehensive analysis, to minimize existing knowledge gaps concerning immune response to metals. To do this, we will apply cutting edge genomic, proteomic and bioinformatic technologies to curate signature sets of genetic and protein markers, and subsequently identify downstream immune/cell regulatory pathways activated through metal sensitivity. To capture these data we will employ 2 models: both human PBL and a transgenic Toll Like Receptor 4 mouse model.
During this research appointment the participant will learn how to conduct studies with both mice and immune cells in to measure the effects of metal particles and ions on immune responses and in particular, generation of distinct biomarkers. They will learn how to use flow cytometry, PCR, proteomics, next generation sequencing and other molecular biology methods as well as bio-informatic tools to facilitate their experiments. They will observe and learn about metal implant associated immune-sensitivity. The participant will not be involved in regulatory activities or provide advisory services on regulatory submissions.
Anticipated Appointment Start Date: September 21, 2020
This program, administered by ORAU through its contract with the U.S. Department of Energy to manage the Oak Ridge Institute for Science and Education, was established through an interagency agreement between DOE and FDA. The initial appointment is for one year, but may be renewed upon recommendation of FDA contingent on the availability of funds. The participant will receive a monthly stipend commensurate with educational level and experience. Proof of health insurance is required for participation in this program. The appointment is full-time at FDA in the Silver Spring, Maryland, area. Participants do not become employees of FDA, DOE or the program administrator, and there are no employment-related benefits.
Completion of a successful background investigation by the Office of Personnel Management is required for an applicant to be on-boarded at FDA. OPM can complete a background investigation only for individuals, including non-US Citizens, who have resided in the US for a total of three of the past five years.
FDA requires ORISE participants to read and sign their FDA Education and Training Agreement within 30 days of his/her start date, setting forth the conditions and expectations for his/her educational appointment at the agency. This agreement covers such topics as the following:
Non-employee nature of the ORISE appointment;
Prohibition on ORISE Fellows performing inherently governmental functions;
Obligation of ORISE Fellows to convey all necessary rights to the FDA regarding intellectual property conceived or first reduced to practice during their fellowship;
The fact that research materials and laboratory notebooks are the property of the FDA;
ORISE fellow’s obligation to protect and not to further disclose or use non-public information.
The qualified candidate should have received a doctoral degree in one of the relevant fields, or be currently pursuing the degree and will reach completion by the appointment start date. Degree must have been received within five years of the appointment start date.
Previous experience, training and publications related to miRNA characterization: including isolation, identification via ion torrent / Illumina sequencing and real time PCR analysis and miRNA computational analysis
Familiarity with bioinformatics software and tools (i.e. Galaxy, EMBL, etc.)
Knowledge of coding (R and Python)
Prior training in molecular toxicology, molecular pharmacology, molecular biology
Excellent written and oral communication skills